Clearmind Medicine has announced a strategic engagement with JS First. This partnership aims to source global manufacturers and distributors for Clearmind’s groundbreaking MEAI-based alcohol substitute beverages, marking a significant step towards international expansion. This move follows Clearmind’s recent announcement regarding its entry into the non-alcoholic beverage market with its proprietary, neurologically active novel alcohol replacement beverage, which was granted patents in the U.S., India and Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
- Clearmind Medicine obtains IND approval from FDA to start Phase I/IIa trial
- Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
- Clearmind Medicine submits US patent application for combination with SciSparc
- Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss